Acute heart failure (AHF) is one of the leading causes of hospitalization in the United States, representing a significant healthcare burden. AHF patients experience high rates of mortality and morbidity. These rates have not changed significantly in recent years because none of the currently approved AHF therapies have been able to improve clinical outcomes. Therefore, the main focus of current treatment of AHF remains symptomatic relief. This content shows how AHF is currently being treated and what drives the choice of pharmacotherapy for AHF patients. We reveal how and when AHF agents are being used, from the initiation of therapy, typically with loop diuretics, through to further lines of treatment. We unravel how pharmacotherapy choices are dictated by patient characteristics given the heterogeneity of symptoms in AHF.
Markets covered: United States
Methodology: Survey of 101 cardiologists in the United States, completed in February 2017
Indication coverage: Acute heart failure
Key drugs covered: Inotropic sympathomimetics, loop diuretics, Natrecor, nitrate vasodilators, PDE3 inhibitors
Key companies mentioned: Cardiorentis, Janssen, Novartis, Sanofi, Valeant